Alan Landay to Drug Resistance, Viral
This is a "connection" page, showing publications Alan Landay has written about Drug Resistance, Viral.
Connection Strength
0.183
-
Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses. 2009 Feb; 25(2):135-9.
Score: 0.085
-
HIV immunology better understood and vaccination attempts started. AIDS. 2002; 16 Suppl 4:S85-8.
Score: 0.052
-
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1184-95.
Score: 0.027
-
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther. 2007; 12(4):531-41.
Score: 0.018